Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Arcturus Therapeutics Ltd
ARCT | US
8.36
USD0.14
1.70%
ARCT | US
About Arcturus Therapeutics Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
8.36
Open
8.30
High
8.43
Low
8.19
Arcturus Therapeutics Holdings Inc. a late-stage clinical messenger RNA medicines and vaccine company focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC) a mRNA-based therapeutic candidate which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19) a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19 as well as ARCT-032 (LUNAR-CF) a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego California.
View LessARCT | US
Risk
65.1
Sharpe
-0.12
Luna's Score
46/100
Recommendation
Hold
Luna says (ARCT | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
70.0%1 month
65.1%3 months
58.7%6 months
95.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
2.48
Price to book
2.21
Debt to equity
0.12
Debt to assets
0.08
Ent. to EBITDA
-25.67
Ent. to rev.
2.33
PEG
-
Other Fundamentals
EBITDA
-85.67M
MarketCap
226.07M
MarketCap(USD)
226.07M
Div. yield
-
Op. margin
-42.37
Erngs. growth
-
Rev. growth
374.00
Ret. on equity
-26.47
Short ratio
11.77
Short perc.
26.67
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
2.47
Range1M
2.69
Range3M
2.69
Volumes: Market Activity
Rel. volume
0.68
Price X volume
3.12M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -25.67 | - | Cheaper |
| Ent. to Revenue | 2.33 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.21 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 58.66 | - | Par |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 226.07M | - | Emerging |
